Skip to main content

Pheochromocytoma clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for
  • Preoperative Alpha Blockade for Pheochromocytoma

    open to eligible people ages 18 years and up

    Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and mortality. Phenoxybenzamine is a non-selective alpha blocker that is significantly more expensive and is associated with increased adverse effects in comparison with selective alpha blockers such as doxazosin. Retrospective studies show minimal differences in hemodynamic instability and no differences in postoperative morbidity and mortality between selective vs. non-selective alpha blockers. This study is a randomized controlled trial that will compare hemodynamic instability, morbidity, mortality, cost, and quality of life between patients blocked with phenoxybenzamine vs. doxazosin.

    at UCLA

  • Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

    Sorry, not accepting new patients

    This is a compassionate use protocol to allow palliative therapy for patients with malignant pheochromocytoma and paragangliomas.

    at UCSF

Our lead scientists for Pheochromocytoma research studies include .

Last updated: